• Monday, March 20, 2023 @ 12:00 am


Key driver evenamide continues to provide compelling data in treatment-resistant schizophrenia, with “Study 014” reporting positive results. Further progress of evenamide with the first pivotal “Study 008A" in schizophrenia to report in H2 2023 and “Study 003” in TRS to start in 2023 add to the value.

Key catalysts for evenamide include:

1. Start pivotal “Study 003” trial in TRS (2023)
2. Results pivotal “Study 008A” trial in non-TRS (H2 2023)
3. Long-term results “Study 015” in TRS (Q1 2024)

Full Newron valuation report

You may also be interested in